Notice for International Patients & Caregivers

English summary does not mean the trial enrolls international patients. Multiple myeloma interventional clinical trials in China typically require valid Chinese resident identity/national healthcare insurance and strict adherence to China's Human Genetic Resources Administration regulations.

Provincial Landscape

Snapshot: 2026-10-21

Shanghai Multiple Myeloma Active Trials & Centers

As of 2026-10-21, there are 32 active clinical trials for multiple myeloma hosted across 13 tertiary medical centers in Shanghai (including Shanghai Fourth People's Hospital, Zhongshan Hospital, Fudan University, Shanghai Changzheng Hospital, etc.).

Active Trials

Hospitals

Therapies

CAR-T Cell Therapy / Bispecific & Multispecific Antibodies / Monoclonal Antibodies / Oral Small-Molecule Agents

Participating Medical Centers (13)

Shanghai Fourth People's HospitalZhongshan Hospital, Fudan UniversityShanghai Changzheng HospitalRenji Hospital, Shanghai Jiao Tong University School of MedicineRuijin Hospital, Shanghai Jiao Tong University School of MedicineShanghai Sixth People's HospitalShanghai Tongji HospitalShanghai Fourth People's Hospital Affiliated to Tongji UniversityFudan University Shanghai Cancer CenterGongli Hospital of Shanghai Pudong New AreaShanghai General HospitalShanghai Minhang District Central HospitalShanghai Tongji Hospital

Active Studies in Shanghai (32)

Population synthesized by CMDN

Showing 0 published English records of 32 registry trials.

All 32 local registry studies currently have Chinese-only filings. Verified English summaries will be published upon regulatory audit.

Back to National Landscape Filter Local Trials in the Trial Hub